News | July 16, 2014

Three-year Outcomes for the AF Convergent Procedure Presented at Atrial Fibrillation Symposium

University Medical Center Ljubljana reports longest convergent procedure follow-up to date at the Atrial Fibrillation Symposium 19th Annual Meeting

July 16, 14 — A new physician poster presentation at the Atrial Fibrillation Symposium 19th Annual International Meeting in Orlando, Fla., reports long-term outcomes for the convergent procedure, a multidisciplinary epicardial-endocardial approach to treat patients with persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, recently estimated to affect 33.5 million people worldwide, with a majority of patients falling into the difficult-to-treat persistent AF population.

In this presentation from the University Medical Center Ljubljana in Ljubljana, Slovenia, 76 patients with persistent and longstanding persistent AF were evaluated through continuous loop recorders. At 36 months' follow-up, 84% of patients were in sinus rhythm and only 10% of patients required repeat ablations.

"We continue to see the positive clinical impact of the Convergent Procedure in our persistent AF patients with this three-year data," said Professor Borut Gersak, M.D., Ph.D., of University Medical Center Ljubljana in Ljubljana, Slovenia. "The Convergent Procedure should be a first-line treatment for persistent AF patients. Our long-term results are aligned with other recent publications in the U.S., and we see high single-procedure efficacy compared to endocardial catheter ablation."

The multidisciplinary Convergent Procedure is performed as a single procedure in the electrophysiology lab. The epicardial lesions are created first under direct endoscopic visualization by a surgeon, through a 2 cm incision in the abdomen, with no chest incisions or ports. The endocardial lesions created by an electrophysiologist help confirm lesion set completeness through specialized EP diagnostics, which also predict outcomes.

For more informationon: www.ncontactinc.com


Related Content

News

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
News

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
News

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
News

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
News

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
News

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
News

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Subscribe Now